{
  "resourceType" : "ResearchStudy",
  "id" : "Fall2-ResearchStudy-KEYNOTE522",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ResearchStudy Fall2-ResearchStudy-KEYNOTE522</b></p><a name=\"Fall2-ResearchStudy-KEYNOTE522\"> </a><a name=\"hcFall2-ResearchStudy-KEYNOTE522\"> </a><p><b>title</b>: KEYNOTE-522: Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy for Triple-Negative Breast Cancer</p><p><b>status</b>: Active</p><p><b>condition</b>: <span title=\"Codes:{http://snomed.info/sct 254837009}\">Malignant neoplasm of breast</span></p></div>"
  },
  "title" : "KEYNOTE-522: Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy for Triple-Negative Breast Cancer",
  "status" : "active",
  "condition" : [{
    "coding" : [{
      "system" : "http://snomed.info/sct",
      "code" : "254837009",
      "display" : "Malignant neoplasm of breast"
    }]
  }]
}